Literature DB >> 20056758

Assessment of renal pathology and dysfunction in children with Fabry disease.

Uma Ramaswami1, Behzad Najafian, Arrigo Schieppati, Michael Mauer, Daniel G Bichet.   

Abstract

Overt renal disease often first presents in male individuals with Fabry disease in early to middle adulthood, but proteinuria and reduced GFR may occur in adolescents and in young children. More recently, kidney biopsy data have shown early renal histologic changes in pediatric patients, and kidney dysfunction, primarily proteinuria, seems to be more common in girls. Renal investigations and their timing in children remain poorly defined. A consensus on renal investigations is necessary to understand the natural progression of the disease and to evaluate the efficacy of treatments such as enzyme replacement therapies. This article addresses three main categories: Use of GFRs, measuring albuminuria, and renal biopsies in children.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20056758      PMCID: PMC4909119          DOI: 10.2215/CJN.08091109

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  45 in total

1.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

Review 2.  How to estimate GFR in children.

Authors:  Joris R Delanghe
Journal:  Nephrol Dial Transplant       Date:  2008-05-29       Impact factor: 5.992

3.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

4.  [Fetal pathology in Fabry's disease and mucopolysaccharidosis type I].

Authors:  M Elleder; H Poupĕtová; V Kozich
Journal:  Cesk Patol       Date:  1998-01

5.  Early renal changes in hemizygous and heterozygous patients with Fabry's disease.

Authors:  M C Gubler; G Lenoir; J P Grünfeld; A Ulmann; D Droz; R Habib
Journal:  Kidney Int       Date:  1978-03       Impact factor: 10.612

6.  Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.

Authors:  U Ramaswami; S Wendt; G Pintos-Morell; R Parini; C Whybra; J A Leon Leal; F Santus; M Beck
Journal:  Acta Paediatr       Date:  2007-01       Impact factor: 2.299

Review 7.  Measurement and estimation of GFR in children and adolescents.

Authors:  George J Schwartz; Dana F Work
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-09       Impact factor: 8.237

8.  Early renal failure in Fabry's disease.

Authors:  K J Sheth; D A Roth; M B Adams
Journal:  Am J Kidney Dis       Date:  1983-05       Impact factor: 8.860

9.  Surveillance renal transplant biopsies and subclinical rejection at three months post-transplant in pediatric recipients.

Authors:  Leonard C Hymes; Laurence Greenbaum; Sandra G Amaral; Barry L Warshaw
Journal:  Pediatr Transplant       Date:  2007-08

10.  Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.

Authors:  C M Eng; J Fletcher; W R Wilcox; S Waldek; C R Scott; D O Sillence; F Breunig; J Charrow; D P Germain; K Nicholls; M Banikazemi
Journal:  J Inherit Metab Dis       Date:  2007-03-08       Impact factor: 4.750

View more
  15 in total

1.  Awareness of Fabry disease among rheumatologists--current status and perspectives.

Authors:  Rolando Cimaz; Severine Guillaume; Max J Hilz; Gerd Horneff; Bernhard Manger; J Carter Thorne; Anette Torvin Møller; Nico M Wulffraat; Johannes Roth
Journal:  Clin Rheumatol       Date:  2011-04       Impact factor: 2.980

2.  Agalsidase benefits renal histology in young patients with Fabry disease.

Authors:  Camilla Tøndel; Leif Bostad; Kristin Kampevold Larsen; Asle Hirth; Bjørn Egil Vikse; Gunnar Houge; Einar Svarstad
Journal:  J Am Soc Nephrol       Date:  2013-01       Impact factor: 10.121

3.  Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?

Authors:  Juan Politei; Valeria Alberton; Oscar Amoreo; Norberto Antongiovanni; Maria Nieves Arán; Marcelo Barán; Gustavo Cabrera; Silvia Di Pietrantonio; Consuelo Durand; Alejandro Fainboim; Joaquin Frabasil; Fernando Gomez Pizarro; Roberto Iotti; Miguel Liern; Fernando Perretta; Diego Ripeau; Fernanda Toniolo; Hernan Trimarchi; Dana Velasques Rivas; Eric Wallace; Andrea Beatriz Schenone
Journal:  Pediatr Nephrol       Date:  2018-07-09       Impact factor: 3.714

Review 4.  Fabry disease-what cardiologists can learn from the nephrologist: a narrative review.

Authors:  Christine E Kurschat
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

Review 5.  Clinical practice: proteinuria.

Authors:  Gema Ariceta
Journal:  Eur J Pediatr       Date:  2010-11-10       Impact factor: 3.183

Review 6.  The renal biopsy in the genomic era.

Authors:  Helen Liapis; Joseph P Gaut
Journal:  Pediatr Nephrol       Date:  2012-11-21       Impact factor: 3.714

Review 7.  Update on role of agalsidase alfa in management of Fabry disease.

Authors:  Uma Ramaswami
Journal:  Drug Des Devel Ther       Date:  2011-03-14       Impact factor: 4.162

Review 8.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

Review 9.  Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel.

Authors:  Alessandro P Burlina; Katherine B Sims; Juan M Politei; Gary J Bennett; Ralf Baron; Claudia Sommer; Anette Torvin Møller; Max J Hilz
Journal:  BMC Neurol       Date:  2011-05-27       Impact factor: 2.474

Review 10.  Fabry disease and kidney involvement: starting from childhood to understand the future.

Authors:  Roberto Chimenz; Valeria Chirico; Caterina Cuppari; Giorgia Ceravolo; Daniela Concolino; Paolo Monardo; Antonio Lacquaniti
Journal:  Pediatr Nephrol       Date:  2021-04-30       Impact factor: 3.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.